Asian SCHOOL

OF PERITONEAL SURFACE ONCOLOGY

And

Asian PERITONEAL SURFACE ONCOLOGY

TRAINING PROGRAM

A Joint venture of Peritoneal Surface Oncology Group International



And

European School of PERITONEAL SURFACE ONCOLOGY

May 18, 2016

Asian SCHOOL OF PERITONEAL SURFACE ONCOLOGY

Web Site:

ESPSO

10th International Congress on Peritoneal Surface Malignancies - Faculty

AIMS

 To provide structured high quality basic and advanced training in Peritoneal Surface Oncology.

To certify proficient knowledge of applying candidates in the scientific basis and clinical practice of Peritoneal Surface Oncology, specifically multidisciplinary decision-making and surgical management.

DEFINITIONS

Peritoneal Surface Oncology: Field of Oncology dealing with the knowledge of peritoneal neoplasms, primary or secondary, and their clinical management in a comprehensive fashion, ranging from their molecular basis and pathological characterization to multidisciplinary clinical management and palliative care. Basic and clinical research are an integral part of this discipline.

See Core Curriculum for further definitions

BACKGROUND

The Asian School of Peritoneal Surface Oncology (ESPSO) arises as a joint venture of the Peritoneal Surface Oncology Group International (PSOGI). It serves the need and the demand to provide adequate and structured training in the management of peritoneal neoplasms, a field that has experienced unprecedented advances and growth in recent years, resulting in the opening of specific treatment programs at many referral centers. It involves highly specialized knowledge and the use of successful complex and aggressive cytoreductive surgery, combined with regional chemotherapy and systemic chemotherapy, as indicated. As shown in other fields of oncology, advanced training is key in the provision of these complex treatments to minimize morbidity and mortality.

PSOGI is the leading international collaborative group in Peritoneal Surface Oncology. It is an umbrella organization for all the Peritoneal Surface Oncology Treatment Programs worldwide, providing an ad hoc forum to exchange current research and practice in the field, set standards and promote new projects.

STRUCTURE AND LEADERSHIP

The ASPSO will be led by a Board composed by:

- ASPSO Directors: Two persons, responsible for all aspects in the development of the School and its activities. (Yutaka Yonemura, MD, PhD, Yan Li, MD, PhD)
- An Advisory Committee, with the role of regulating program contents, assisting
 in candidate selection and evaluation, accreditation of tutors or any other
 aspects as required by the School Directors. Composed of:
 - A multidisciplinary panel including one medical oncologist, one pathologist and one radiologist with special dedication to PSO and an interest in teaching.
 - ASPSO representative
 - o An ASPSO Education and Training Committee representative

Administrative support and logistics for the School operations will be provided by ASPSO (office capabilities, rooms for business meetings, etc). Funding for operational costs (travel for PSOGI meetings, administrative costs, etc) will be covered by ASPSO's educational budget and possibly candidates fees.

ASPSO Directors, tutors or Advisory Committee members will not receive any honoraria for their work, but will have reasonable costs derived from their responsibility and input

MEMBERS AND ADVISORY COMMITTEE

Kanji Katayama, Haruaki Ishibashi, Akiyoshi Mizumoto, Toshiyuki Kitai, Yoshio Endou, Satoshi Murata, Sachio Fushida, Shouzou Sako, Takuji Fujita, Takashi Fujimura (Japan)

Paul H Sugarbaker (USA), Emel Canbay (Turkey), Brendan Moran (UK), Marcello Deraco (Italy), Santiago Moreno-Gonzalez (Spain), Haile Mahtem (Sweden), Pompiliu Piso (Germany), David L Morris (Australia), Frans A.N. Zoetmulder (the Netherland), Oliver Glehen (France), Beate Rau

(Germany), Françoir Gilly (France), Yan Li (China), Dominique Elias (France), David Bartlett (USA), Vic Verwaal (Denmark), Kurt van del Speaten (Belgium), Mao-Chi Shier (Taiwan)

ACTIVITY

ASPSO will provide basic and advanced training to selected applicants through its Asian Peritoneal Surface Oncology Training Program. Upon successful completion of this program, the candidate will obtain the Asian Accreditation in Peritoneal Surface Oncology.

All educational initiatives in Peritoneal Surface Oncology already developed, or to be developed, by PSOGI will automatically be considered ASPSO activities.

ASPSO will be able to develop further educational events or activities in PSO beyond the ones already included in the ASPSO Training Program

PROGRAM

- 1) Exploratory laparoscopy to diagnose peritoneal cancer index. Laparoscopic hyperthermic peritoneal chemo-perfusion (HIPEC).
- 2) Neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), placement of IP port under local anesthesia.
- 3) Indication of cytoreductive surgery (CRS) and HIPEC. Selection of patients. Informed consent.
- 4) Peritonectomy procedures
- 5) Extensive intraperitoneal lavage
- 6) HIPEC after CRS
- 7) Treatment of resected specimens. Pathologic diagnosis and immunohistochemical staining, using specific antibodies against proteins specific for diseases.

- 8) Postoperative care.
- 9) Postoperative chemotherapy and follow-up.
- 10) Statistical analyses
- 11) Presentation at congress. Manuscript submission.
- 12) Protocol and ethical committee.

DURATION OF TRAINING AND NUMBER OF CRS

Duration for training depends on the schedule of applicants. It needs six months to 2 years to complete training. Applicants should join at least 60~130 CRS and HIPEC.

DISEASES

Peritoneal metastases from colo-rectal cancer, gastric cancer, ovarian cancer, pancreas cancer, hepato-biliary cancer and uterine cancer, and mesothelioma, primary peritoneal carcinomatosis, granulose cell tumor, and sarcoma.

HOW TO REGISTER

Admission decisions are based on a combination of criteria: academic degree and performance, motivation, and work experience.

Application must include

- 1) E-mail letter including motivation for attending
- 2) Short CV (max 2 pages) describing recent experience and list of recent publication.

Send e-mail to Yutaka Yonemura MD, PhD. y.yonemura@coda.ocn.ne.jp

REGISTRATION FEE

10,000 yen for text books should be paid at registration in September. It is not necessary to pay any money except text book fee.

For medical doctors having Japanese medical license, he or she can get 70,000 yen per day from ASPSO recognized hospitals during training period.

RECOGNIZED HOSPITALS

Regional Cancer Therapies, Peritoneal Surface Malignancy Center, Kishiwada Tokushukai Hospital.

Regional Cancer Therapies, Peritoneal Surface Malignancy Center, Kusatsu general Hospital.

Japanese Ministry of Health, Labour and welfare authorized these hospitals as institutions under the provision of the Law concerning the Exceptional Cases of the Medical Practioners Act, Article 17, on the Advanced Clinical Training of Foreign Medical Practitioners.